Light Sciences Oncology
Pharmaceutical ManufacturingWashington, United States11-50 Employees
Light Sciences Oncology (LSO) is developing Aptocine™ (talaporfin sodium) for the treatment of solid tumors as well as other indications such as benign prostatic hyperplasia (BPH). Aptocine is a water-soluble drug energized by a small, single-use, disposable drug activator included with the drug. Aptocine is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment in Phase 3 trials of Aptocine in patients with hepatocellular carcinoma (HCC) and patients with metastatic colorectal cancer (MCRC). LSO is also conducting clinical trials of Aptocine in benign prostatic hyperplasia (BPH), or enlargement of the prostate, and is supporting a trial of Aptocine in neurofibromatosis, and has clinical or preclinical programs in cardiovascular disease, eye disease, and dermatology. The Company has positioned Aptocine to benefit an increasing number of patients with a strong portfolio of intellectual property and innovative applications in development.
1-888-653-2347 
support@leadiq.com 
